PF-Atlas › Clinical Trials › NCT00645788
Study to Evaluate the Safety and Efficacy of Ciprofloxacin in Patients With Cystic Fibrosis
Ciprofloxacin · Phase 2
Registry ID
NCT00645788
Phase
Phase 2
Status
Completed
Drug / intervention
Ciprofloxacin (Cipro Inhale, BAYQ3939)
Sponsor
Bayer
Start
2008-05
Enrollment
288
Locations
86
About this trial
To evaluate the change in forced expiratory volume (FEV1) from baseline to Day 28-30 between Cipro Inhale-treated and placebo-treated subjects after a 4-week treatment period.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT00645788 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.